Cargando…
Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy
BACKGROUND: In situ tumor vaccine has been gradually becoming a hot research field for its advantage of achieving personalized tumor therapy without prior antigen identification. Various in situ tumor vaccine regimens have been reported to exert considerable antitumor efficacy in preclinical and cli...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498626/ https://www.ncbi.nlm.nih.gov/pubmed/37700338 http://dx.doi.org/10.1186/s12967-023-04504-w |